Published in Circulation on November 13, 2001
Impact of Diabetes on Left Ventricular Remodeling (P3) | NCT01052272
Oxygen, oxidative stress, hypoxia, and heart failure. J Clin Invest (2005) 5.53
Effect of high-dose allopurinol on exercise in patients with chronic stable angina: a randomised, placebo controlled crossover trial. Lancet (2010) 4.74
Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev (2006) 3.27
Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J Physiol (2003) 3.19
Uric acid and inflammatory markers. Eur Heart J (2006) 2.81
Reactive oxygen species in cardiovascular disease. Free Radic Biol Med (2011) 2.29
NO/redox disequilibrium in the failing heart and cardiovascular system. J Clin Invest (2005) 1.94
Neuronal nitric oxide synthase negatively regulates xanthine oxidoreductase inhibition of cardiac excitation-contraction coupling. Proc Natl Acad Sci U S A (2004) 1.91
Allopurinol acutely increases adenosine triphospate energy delivery in failing human hearts. J Am Coll Cardiol (2012) 1.66
Inflammation as a therapeutic target in heart failure? A scientific statement from the Translational Research Committee of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail (2009) 1.61
Oxidative stress as a mediator of cardiovascular disease. Oxid Med Cell Longev (2010) 1.58
Increased oxidative stress and cardiomyocyte myofibrillar degeneration in patients with chronic isolated mitral regurgitation and ejection fraction >60%. J Am Coll Cardiol (2010) 1.52
Role of oxidative-nitrosative stress and downstream pathways in various forms of cardiomyopathy and heart failure. Curr Vasc Pharmacol (2005) 1.42
NADPH oxidase plays a central role in cone cell death in retinitis pigmentosa. J Neurochem (2009) 1.32
Allopurinol reduces B-type natriuretic peptide concentrations and haemoglobin but does not alter exercise capacity in chronic heart failure. Heart (2005) 1.26
Role of urate, xanthine oxidase and the effects of allopurinol in vascular oxidative stress. Vasc Health Risk Manag (2009) 1.24
Potential role of uric acid in metabolic syndrome, hypertension, kidney injury, and cardiovascular diseases: is it time for reappraisal? Curr Hypertens Rep (2013) 1.20
NADPH oxidase-derived reactive oxygen species in cardiac pathophysiology. Philos Trans R Soc Lond B Biol Sci (2005) 1.17
Redox signaling in cardiovascular health and disease. Free Radic Biol Med (2013) 1.16
NADPH oxidases and cardiac remodelling. Heart Fail Rev (2011) 1.14
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease? Br J Clin Pharmacol (2006) 1.09
Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) (2009) 1.08
Metabolic rates of ATP transfer through creatine kinase (CK Flux) predict clinical heart failure events and death. Sci Transl Med (2013) 1.08
The efficacy of edaravone (radicut), a free radical scavenger, for cardiovascular disease. Int J Mol Sci (2013) 1.07
Xanthine oxidase inhibitor allopurinol attenuates the development of diabetic cardiomyopathy. J Cell Mol Med (2008) 1.05
Xanthine oxidase inhibition with febuxostat attenuates systolic overload-induced left ventricular hypertrophy and dysfunction in mice. J Card Fail (2008) 1.03
Biochemical and mechanical dysfunction in a mouse model of desmin-related myopathy. Circ Res (2009) 1.02
Redox regulation of sodium and calcium handling. Antioxid Redox Signal (2012) 1.00
'Ryanopathy': causes and manifestations of RyR2 dysfunction in heart failure. Cardiovasc Res (2013) 0.96
Association of serum uric acid with incident atrial fibrillation (from the Atherosclerosis Risk in Communities [ARIC] study). Am J Cardiol (2011) 0.96
Nitroso-redox imbalance affects cardiac structure and function. J Am Coll Cardiol (2013) 0.93
Compartment-specific Control of Reactive Oxygen Species Scavenging by Antioxidant Pathway Enzymes. J Biol Chem (2016) 0.93
Oxidative stress in heart failure: what are we missing? Am J Med Sci (2011) 0.92
Xanthine oxidase and the fetal cardiovascular defence to hypoxia in late gestation ovine pregnancy. J Physiol (2013) 0.91
Novel insights into interactions between mitochondria and xanthine oxidase in acute cardiac volume overload. Free Radic Biol Med (2011) 0.91
Remodeling of calcium handling in human heart failure. Adv Exp Med Biol (2012) 0.91
Effects of Xanthine Oxidase Inhibition in Hyperuricemic Heart Failure Patients: The Xanthine Oxidase Inhibition for Hyperuricemic Heart Failure Patients (EXACT-HF) Study. Circulation (2015) 0.89
Xanthine oxidase inhibition preserves left ventricular systolic but not diastolic function in cardiac volume overload. Am J Physiol Heart Circ Physiol (2013) 0.89
Angiotensin II and oxidative stress in the failing heart. Antioxid Redox Signal (2012) 0.88
Increased levels of uric acid predict haemodynamic compromise in patients with heart failure independently of B-type natriuretic peptide levels. Heart (2007) 0.87
Antiarrhythmic and anti-ischaemic effects of angina in patients with and without coronary collaterals. Heart (2002) 0.87
Posttranslational modifications of cardiac ryanodine receptors: Ca(2+) signaling and EC-coupling. Biochim Biophys Acta (2012) 0.86
The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease. Cardiovasc Psychiatry Neurol (2009) 0.86
Diesterified nitrone rescues nitroso-redox levels and increases myocyte contraction via increased SR Ca(2+) handling. PLoS One (2012) 0.86
Acute and chronic endothelial dysfunction: implications for the development of heart failure. Heart Fail Rev (2003) 0.86
Hydralazine and organic nitrates restore impaired excitation-contraction coupling by reducing calcium leak associated with nitroso-redox imbalance. J Biol Chem (2013) 0.85
Xanthine oxidase activity is influenced by environmental factors in Ethiopians. Eur J Clin Pharmacol (2003) 0.85
Activation of cGMP/protein kinase G pathway in postconditioned myocardium depends on reduced oxidative stress and preserved endothelial nitric oxide synthase coupling. J Am Heart Assoc (2013) 0.84
Higher serum uric acid and lipoprotein(a) are correlated with coronary spasm. Heart Vessels (2013) 0.84
Xanthine oxidase inhibition for chronic heart failure: is allopurinol the next therapeutic advance in heart failure? Heart (2005) 0.83
Xanthine oxidase inhibition for hyperuricemic heart failure patients: design and rationale of the EXACT-HF study. Circ Heart Fail (2013) 0.83
Inhibition of xanthine oxidase improves myocardial contractility in patients with ischemic cardiomyopathy. Free Radic Biol Med (2006) 0.82
Role of xanthine oxidoreductase in cardiac nitroso-redox imbalance. Front Biosci (Landmark Ed) (2009) 0.81
How exercise may amend metabolic disturbances in diabetic cardiomyopathy. Antioxid Redox Signal (2015) 0.80
Reactive Oxygen-Related Diseases: Therapeutic Targets and Emerging Clinical Indications. Antioxid Redox Signal (2015) 0.79
Combination of uric acid and NT-ProBNP: a more useful prognostic marker for short-term clinical outcomes in patients with acute heart failure. Korean J Intern Med (2010) 0.79
Allopurinol and global left myocardial function in heart failure patients. J Cardiovasc Dis Res (2010) 0.79
Pharmacology and Clinical Drug Candidates in Redox Medicine. Antioxid Redox Signal (2015) 0.79
Xanthine Oxidase Inhibitor, Allopurinol, Prevented Oxidative Stress, Fibrosis, and Myocardial Damage in Isoproterenol Induced Aged Rats. Oxid Med Cell Longev (2015) 0.78
Review of novel therapeutic targets for improving heart failure treatment based on experimental and clinical studies. Ther Clin Risk Manag (2016) 0.78
Antioxidants in Cardiovascular Therapy: Panacea or False Hope? Front Cardiovasc Med (2015) 0.78
Role of nitric oxide in the pathophysiology of heart failure. Heart Fail Rev (2003) 0.78
Delayed treatment effects of xanthine oxidase inhibition on systolic overload-induced left ventricular hypertrophy and dysfunction. Nucleosides Nucleotides Nucleic Acids (2010) 0.78
Uric acid in heart failure: a biomarker or therapeutic target? Heart Fail Rev (2013) 0.78
Human Ischemic Cardiomyopathy Shows Cardiac Nos1 Translocation and its Increased Levels are Related to Left Ventricular Performance. Sci Rep (2016) 0.78
Mechanisms of cardioprotection resulting from Brown Norway chromosome 16 substitution in the salt-sensitive Dahl rat. Physiol Genomics (2012) 0.77
Xanthine oxidase inhibitors in heart failure: where do we go from here? Circulation (2015) 0.77
Role of Oxidative Stress in Thyroid Hormone-Induced Cardiomyocyte Hypertrophy and Associated Cardiac Dysfunction: An Undisclosed Story. Oxid Med Cell Longev (2015) 0.76
Steps forward in the treatment of pulmonary arterial hypertension: latest developments and clinical opportunities. Ther Adv Chronic Dis (2017) 0.75
Cardiac resynchronization therapy in heart failure: recent advances and new insights. Indian Pacing Electrophysiol J (2003) 0.75
Xanthine oxidase inhibition for the treatment of cardiovascular disease: an updated systematic review and meta-analysis. ESC Heart Fail (2016) 0.75
Measurement and Clinical Significance of Biomarkers of Oxidative Stress in Humans. Oxid Med Cell Longev (2017) 0.75
Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med (2000) 6.27
Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function. Circulation (1997) 4.63
Long-term outcome of fulminant myocarditis as compared with acute (nonfulminant) myocarditis. N Engl J Med (2000) 3.70
Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res (1999) 3.43
Effective arterial elastance as index of arterial vascular load in humans. Circulation (1992) 3.42
Molecular and cellular mechanisms of myocardial stunning. Physiol Rev (1999) 3.16
Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, I: experimental studies. Circ Res (1999) 3.03
Ionic mechanism of action potential prolongation in ventricular myocytes from dogs with pacing-induced heart failure. Circ Res (1996) 2.91
Left ventricular or biventricular pacing improves cardiac function at diminished energy cost in patients with dilated cardiomyopathy and left bundle-branch block. Circulation (2000) 2.90
Sudden cardiac death in heart failure. The role of abnormal repolarization. Circulation (1994) 2.78
Mechanisms of altered excitation-contraction coupling in canine tachycardia-induced heart failure, II: model studies. Circ Res (1999) 2.65
Noninvasive single-beat determination of left ventricular end-systolic elastance in humans. J Am Coll Cardiol (2001) 2.64
Transfer function analysis of the circulation: unique insights into cardiovascular regulation. Am J Physiol (1991) 2.42
The causes of dilated cardiomyopathy: a clinicopathologic review of 673 consecutive patients. J Am Coll Cardiol (1994) 2.38
The in vivo role of p38 MAP kinases in cardiac remodeling and restrictive cardiomyopathy. Proc Natl Acad Sci U S A (2001) 2.36
Inducible genetic suppression of neuronal excitability. J Neurosci (1999) 2.32
An efficient algorithm for spectral analysis of heart rate variability. IEEE Trans Biomed Eng (1986) 2.31
Coupled systolic-ventricular and vascular stiffening with age: implications for pressure regulation and cardiac reserve in the elderly. J Am Coll Cardiol (1998) 2.26
Beat-to-beat repolarization lability identifies patients at risk for sudden cardiac death. J Cardiovasc Electrophysiol (1998) 2.25
Assessment of autonomic regulation in chronic congestive heart failure by heart rate spectral analysis. Am J Cardiol (1988) 2.25
In vivo murine left ventricular pressure-volume relations by miniaturized conductance micromanometry. Am J Physiol (1998) 2.22
Targeted disruption of the Kvlqt1 gene causes deafness and gastric hyperplasia in mice. J Clin Invest (2000) 2.17
Endogenous nitric oxide mechanisms mediate the stretch dependence of Ca2+ release in cardiomyocytes. Nat Cell Biol (2001) 2.14
Echocardiographic findings in fulminant and acute myocarditis. J Am Coll Cardiol (2000) 2.12
Visualization and temporal/spatial characterization of cardiac radiofrequency ablation lesions using magnetic resonance imaging. Circulation (2000) 1.96
The pathogenesis of familial hypertrophic cardiomyopathy: early and evolving effects from an alpha-cardiac myosin heavy chain missense mutation. Nat Med (1999) 1.93
Predictors of systolic augmentation from left ventricular preexcitation in patients with dilated cardiomyopathy and intraventricular conduction delay. Circulation (2000) 1.89
Molecular composition of mitochondrial ATP-sensitive potassium channels probed by viral Kir gene transfer. J Mol Cell Cardiol (2000) 1.88
Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J (2001) 1.81
Contribution of external forces to left ventricular diastolic pressure. Implications for the clinical use of the Starling law. Ann Intern Med (1995) 1.75
Beat to beat variability in cardiovascular variables: noise or music? J Am Coll Cardiol (1989) 1.72
Single-beat estimation of end-systolic pressure-volume relation in humans. A new method with the potential for noninvasive application. Circulation (1996) 1.71
Tanapox: a new disease caused by a pox virus. Br Med J (1971) 1.71
Modulation of mitochondrial ATP-dependent K+ channels by protein kinase C. Circ Res (1998) 1.71
Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ Res (1999) 1.71
Acute endothelin A receptor blockade causes selective pulmonary vasodilation in patients with chronic heart failure. Circulation (2000) 1.69
Verapamil acutely reduces ventricular-vascular stiffening and improves aerobic exercise performance in elderly individuals. J Am Coll Cardiol (1999) 1.69
Nitroxyl anion exerts redox-sensitive positive cardiac inotropy in vivo by calcitonin gene-related peptide signaling. Proc Natl Acad Sci U S A (2001) 1.63
Transgenic mouse model of stunned myocardium. Science (2000) 1.62
Selective pharmacological agents implicate mitochondrial but not sarcolemmal K(ATP) channels in ischemic cardioprotection. Circulation (2000) 1.61
Mitochondrial ATP-sensitive potassium channels attenuate matrix Ca(2+) overload during simulated ischemia and reperfusion: possible mechanism of cardioprotection. Circ Res (2001) 1.59
Temporal repolarization lability in hypertrophic cardiomyopathy caused by beta-myosin heavy-chain gene mutations. Circulation (2000) 1.58
Functional roles of cardiac and vascular ATP-sensitive potassium channels clarified by Kir6.2-knockout mice. Circ Res (2001) 1.56
Ventricular pacing with premature excitation for treatment of hypertensive-cardiac hypertrophy with cavity-obliteration. Circulation (1999) 1.56
Functional association of the beta 1 subunit with human cardiac (hH1) and rat skeletal muscle (mu 1) sodium channel alpha subunits expressed in Xenopus oocytes. J Gen Physiol (1995) 1.53
Upregulation of the nitric oxide-cGMP pathway in aged myocardium: physiological response to l-arginine. Circ Res (2001) 1.51
Molecular basis of electrocardiographic ST-segment elevation. Circ Res (2000) 1.51
Effect of reduced aortic compliance on cardiac efficiency and contractile function of in situ canine left ventricle. Circ Res (1992) 1.51
Academic boycott of South Africa. Lancet (1989) 1.49
Comparison of ventricular pressure relaxation assessments in human heart failure: quantitative influence on load and drug sensitivity analysis. J Am Coll Cardiol (1999) 1.48
Determination of left ventricular end-systolic pressure-volume relationships by the conductance (volume) catheter technique. Circulation (1986) 1.47
Mitochondrial ATP-sensitive potassium channels inhibit apoptosis induced by oxidative stress in cardiac cells. Circ Res (2001) 1.46
Focal modification of electrical conduction in the heart by viral gene transfer. Nat Med (2000) 1.45
Validation of carotid artery tonometry as a means of estimating augmentation index of ascending aortic pressure. Hypertension (1996) 1.42
Comparison of a counting chamber and thick smear methods of counting microfilariae. Trans R Soc Trop Med Hyg (1971) 1.41
Mesenchymal stem cells for cardiac regenerative therapy. Handb Exp Pharmacol (2007) 1.40
Activation of mitochondrial ATP-dependent potassium channels by nitric oxide. Circulation (2000) 1.39
Cellular basis of ventricular arrhythmias and abnormal automaticity in heart failure. Am J Physiol (1999) 1.38
Complications of transvenous right ventricular endomyocardial biopsy in adult patients with cardiomyopathy: a seven-year survey of 546 consecutive diagnostic procedures in a tertiary referral center. J Am Coll Cardiol (1992) 1.38
Heart rate and muscle sympathetic nerve variability during reflex changes of autonomic activity. Am J Physiol (1990) 1.37
Transfer function analysis of autonomic regulation. II. Respiratory sinus arrhythmia. Am J Physiol (1989) 1.36
Functional properties of cardiac L-type calcium channels transiently expressed in HEK293 cells. Roles of alpha 1 and beta subunits. J Gen Physiol (1995) 1.34
cGMP-independent inotropic effects of nitric oxide and peroxynitrite donors: potential role for nitrosylation. Am J Physiol Heart Circ Physiol (2000) 1.34
Murine cardiac function: a cautionary tail. Circ Res (1998) 1.34
Cardiac sodium channels (hH1) are intrinsically more sensitive to block by lidocaine than are skeletal muscle (mu 1) channels. J Gen Physiol (1995) 1.33
Diminished contractile response to increased heart rate in intact human left ventricular hypertrophy. Systolic versus diastolic determinants. Circulation (1993) 1.32
Pharmacological comparison of native mitochondrial K(ATP) channels with molecularly defined surface K(ATP) channels. Mol Pharmacol (2001) 1.31
Novel myofilament Ca2+-sensitizing property of xanthine oxidase inhibitors. Circ Res (1998) 1.31
Comparison of two murine models of familial hypertrophic cardiomyopathy. Circ Res (2001) 1.30
Myocarditis and long-term survival in peripartum cardiomyopathy. Am Heart J (2000) 1.29
Cardiomyopathy in Irx4-deficient mice is preceded by abnormal ventricular gene expression. Mol Cell Biol (2001) 1.28
Parametric model derivation of transfer function for noninvasive estimation of aortic pressure by radial tonometry. IEEE Trans Biomed Eng (1999) 1.26
Oxidative stress and apoptosis in heart failure progression. Circ Res (2001) 1.25
The spectrum of dilated cardiomyopathy. The Johns Hopkins experience with 1,278 patients. Medicine (Baltimore) (1999) 1.25
The detection of circulating antigen in human hydatid disease. Ann Trop Med Parasitol (1984) 1.25
Pharmacological and histochemical distinctions between molecularly defined sarcolemmal KATP channels and native cardiac mitochondrial KATP channels. Mol Pharmacol (1999) 1.24
Effect of baseline or changes in adrenergic activity on clinical outcomes in the beta-blocker evaluation of survival trial. Circulation (2004) 1.24
Clockwise domain arrangement of the sodium channel revealed by (mu)-conotoxin (GIIIA) docking orientation. J Biol Chem (2001) 1.24
In vivo measurement of water diffusion in the human heart. Magn Reson Med (1994) 1.23
ATP consumption by uncoupled mitochondria activates sarcolemmal K(ATP) channels in cardiac myocytes. Am J Physiol Heart Circ Physiol (2001) 1.22
Molecular interactions between two long-QT syndrome gene products, HERG and KCNE2, rationalized by in vitro and in silico analysis. Circ Res (2001) 1.21
The stuttering progress of cell therapy for heart disease. Clin Pharmacol Ther (2011) 1.20
Ventricular stroke work and efficiency both remain nearly optimal despite altered vascular loading. Am J Physiol (1993) 1.20
Studies on heterologous immunity in schistosomiasis. I. Heterologous schistosome immunity in mice. Bull World Health Organ (1968) 1.19
Adenovirus-mediated inducible gene expression in vivo by a hybrid ecdysone receptor. Mol Ther (2000) 1.19
Altered high-energy phosphate metabolism predicts contractile dysfunction and subsequent ventricular remodeling in pressure-overload hypertrophy mice. Am J Physiol Heart Circ Physiol (2006) 1.18